

Claim

1. A pharmaceutical composition for systemic administration for use in treating a neuropathic pain, which comprises a compound having mGluR1 antagonistic activity in an amount effective for improving the neuropathic pain and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition according to claim 1, wherein the neuropathic pain is a neuropathic pain induced by diabetes or compression of nerves.

3. The pharmaceutical composition according to claim 1, wherein the neuropathic pain is a neuropathic pain induced by diabetes.

4. The pharmaceutical composition according to claim 1, wherein the systemic administration method is oral administration.

5. The pharmaceutical composition according to claim 1, wherein the compound having mGluR1 antagonistic activity is a compound having sufficient mGluR1 antagonism for expressing neuropathic pain improving effect by systemic administration.

6. The pharmaceutical composition according to claim 1, wherein the compound having mGluR1 antagonism is a compound selected from 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzoimidazole-2-carboxamide dihydrochloride and (+)-(1R,2S)-6-amino-N-methyl-N-(2-

methylcyclohexyl)thiazolo[3,2-a]benzoimidazole-2-  
carboxamide dihydrochloride.